CROI 2017 Program and Information

Program and Agenda

Symposium S-5 HEPATITIS/LIVER Room 6 E 4:00 PM - 6:00 PM Target audience: This session is directed to investigators and clinicians who are interested in the epidemiology, basic science, public health impact, and future trends in hepatitis B and hepatitis C therapy. Level of knowledge: It is assumed that participants are familiar with the general principles of hepatitis B and hepatitis C virology and treatment. Objectives: • To identify the limitations and the potential for virologic and immunologic approaches to the cure of HBV infection • To compare the approach to preventing vertical transmission of HIV to HBV • To appreciate the opportunities and challenges to achieving the UN HCV elimination goals • To understand the prevalence of fatty liver disease and recognize the difference between steatosis and steatohepatitis Conveners Marion G. Peters , Univ of California San Francisco, San Francisco, CA, USA Massimo Puoti , ASST GOM Niguarda, Milan, Italy 96 HEPATITIS B: PROGRESS AND PROSPECTS IN HEPATITIS BVIRUS CURE Patrick Kennedy , Queen Mary Univ London, London, United Kingdom 97 MANAGEMENT OF CHRONIC HEPATITIS B DURING PREGNANCY Mindie H. Nguyen , Stanford Univ Med Cntr, Palo Alto, CA, USA 98 HEPATITIS C VIRUS: GONE BY 2030? John W. Ward , CDC, Atlanta, GA, US A 4:00 4:30 5:00

99 FATTY LIVER DISEASE: A GROWING CONCERN Rohit Loomba , Univ of California San Diego, La Jolla, CA 5:30

Oral Sessions • Wednesday

CROI 2017 57